I think that market understands that the decision will not have any affect on real life.
Insurence companies that have to supply will choose what their pations want and if a medicin is better and cheaper the answer is clear.
It is not a headach pill one buy for 5 $ over the counter .
What you say is true for the U.S. and Israel. Unfortunately, it cannot be true in Europe: if the FDA-equivalent has denied marketing it, the doctors/insurers/payors cannot choose it. I am afraid the loss of that market is as real as it can get.